Research Papers:

Krüppel-like factor 4 promotes human osteosarcoma growth and metastasis via regulating CRYAB expression

Lu Zhang, Li Zhang, Xin Xia, Shengwei He, Hongtao He and Wenzhi Zhao _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:30990-31000. https://doi.org/10.18632/oncotarget.8824

Metrics: PDF 1638 views  |   HTML 2194 views  |   ?  


Lu Zhang1, Li Zhang2, Xin Xia1, Shengwei He1, Hongtao He1, Wenzhi Zhao1,3

1Department of Orthopedics, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China

2Laboratory of Pathogenic Biology, College of Basic Medical Science of Dalian Medical University, Dalian 116027, China

3Department of Orthopedics, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, China

Correspondence to:

Wenzhi Zhao, e-mail: [email protected]

Keywords: KLF4, osteosarcoma, migration, CRYAB, proliferation

Received: February 16, 2016    Accepted: March 31, 2016    Published: April 18, 2016


Krüppel-like factor 4 (KLF4), a zinc-finger transcription factor, is an essential regulator in many cellular processes, including differentiation, proliferation, inflammation, pluripotency, and apoptosis. Along with these roles in normal cells and tissues, KLF4 has been reported as a tumor suppressor or an oncogene in many cancers. However, the role of KLF4 in osteosarcoma is largely unknown. Here we found the expression of KLF4 was significantly increased in human osteosarcoma tissues compared with the normal tissues. Elevated KLF4 promoted human osteosarcoma cell proliferation and metastasis. Subsequently, mechanistic studies revealed KLF4 specifically bound the promoter of CRYAB and upregulated CRYAB expression in human osteosarcoma cells. Moreover, we found that KLF4 enhanced osteosarcoma cell proliferation and migration via upregulating CRYAB. Therefore, our studies suggested KLF4 may be a potential target for human osteosarcoma therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8824